{"id":325858,"date":"2022-05-09T09:58:25","date_gmt":"2022-05-09T07:58:25","guid":{"rendered":"https:\/\/medizinonline.com\/levolocumab-stabilise-les-plaques-chez-90-des-patients-souffrant-dun-syndrome-coronarien-aigu\/"},"modified":"2022-05-09T09:58:25","modified_gmt":"2022-05-09T07:58:25","slug":"levolocumab-stabilise-les-plaques-chez-90-des-patients-souffrant-dun-syndrome-coronarien-aigu","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/levolocumab-stabilise-les-plaques-chez-90-des-patients-souffrant-dun-syndrome-coronarien-aigu\/","title":{"rendered":"L&#8217;\u00e9volocumab stabilise les plaques chez 90% des patients souffrant d&#8217;un syndrome coronarien aigu"},"content":{"rendered":"<p><strong><span style=\"color:windowtext\">Apr\u00e8s un syndrome coronarien aigu, les patients pr\u00e9sentent un risque \u00e9lev\u00e9 de d\u00e9velopper d&#8217;autres maladies cardiovasculaires. Les plaques d&#8217;ath\u00e9roscl\u00e9rose jouent un r\u00f4le crucial dans ce processus, car jusqu&#8217;\u00e0 75% des \u00e9pisodes de syndrome coronarien aigu sont d\u00e9clench\u00e9s par une rupture de plaque. On sait d\u00e9j\u00e0 qu&#8217;un faible niveau de LDL-C peut contribuer \u00e0 stabiliser les plaques. L&#8217;\u00e9tude HUYGENS a maintenant pu montrer&nbsp;<\/span><\/strong><strong><span style=\"color:windowtext\">que l&#8217;ajout pr\u00e9coce&nbsp;<\/span><\/strong><strong><span style=\"color:windowtext\">de l&#8217;\u00e9volocumab, un inhibiteur de PCSK9, dans le traitement par statine apr\u00e8s un syndrome coronarien aigu est bien tol\u00e9r\u00e9 et contribue \u00e0 stabiliser les plaques vuln\u00e9rables1<\/span><span style=\"color:windowtext\">. Cela souligne la pertinence d&#8217;une utilisation pr\u00e9coce de l&#8217;inhibiteur de PCSK9 pour une r\u00e9duction maximale du LDL-C chez ces patients cardiovasculaires \u00e0 haut risque.<\/span><\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>Dans la vid\u00e9o suivante, PD Dr med. Gregor Leibundgut, responsable du service de cardiologie de l&#8217;h\u00f4pital cantonal de B\u00e2le-Campagne, pr\u00e9sente les donn\u00e9es de l&#8217;\u00e9tude HUYGENS.<\/p>\n<p><iframe frameborder=\"0\" height=\"1080\" data-src=\"https:\/\/player.vimeo.com\/video\/708205738?h=454a8898ef&amp;badge=0&amp;autopause=0&amp;player_id=0&amp;app_id=58479\" title=\"HUYGENS_Leibundgut_final.mp4\" width=\"1920\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" data-load-mode=\"1\"><\/iframe><\/p>\n<p>&nbsp;<\/p>\n<p><strong>R\u00e9f\u00e9rences :<\/strong><\/p>\n<div><span style=\"font-size:9px\">1. Nicholls, S.J., et al., Assessing the impact of PCSK9 inhibition on coronary plaque phenotype&nbsp;<\/span><span style=\"font-size:9px\">with optical coherence tomography : rationale and design of the randomized, placebo-controlled<\/span><\/div>\n<div><span style=\"font-size:9px\">\u00c9tude HUYGENS. Cardiovasc Diagn Ther, 2021. 11(1) : p. 120 &#8211; 129.<\/span><\/div>\n<div>&nbsp;<\/div>\n<p>Les derni\u00e8res informations professionnelles sur Repatha<sup><span style=\"font-size:10px\"><span style=\"font-family:calibri,sans-serif\">\u00ae<\/span><\/span> <\/sup>sont disponibles sur <a href=\"http:\/\/www.swissmedicinfo.ch\" target=\"_blank\" rel=\"noopener\">www.swissmedicinfo.ch.<\/a><\/p>\n<p>Contribution en ligne depuis le 10\/05\/2022<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Apr\u00e8s un syndrome coronarien aigu, les patients pr\u00e9sentent un risque \u00e9lev\u00e9 de d\u00e9velopper d&#8217;autres maladies cardiovasculaires. Les plaques d&#8217;ath\u00e9roscl\u00e9rose jouent un r\u00f4le crucial dans ce processus, car jusqu&#8217;\u00e0 75% des&hellip;<\/p>\n","protected":false},"author":14,"featured_media":119678,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Patients cardiovasculaires \u00e0 haut risque","footnotes":""},"category":[11357,11378,11404,11315,11549],"tags":[],"powerkit_post_featured":[],"class_list":["post-325858","post","type-post","status-publish","format-standard","has-post-thumbnail","category-angiologie-fr","category-cardiologie","category-endocrinologie-et-diabetologie","category-medecine-interne-generale","category-rx-fr","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-20 21:26:26","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":325864,"slug":"evolocumab-stabilizza-le-placche-nel-90-dei-pazienti-con-sindrome-coronarica-acuta","post_title":"Evolocumab stabilizza le placche nel 90% dei pazienti con sindrome coronarica acuta","href":"https:\/\/medizinonline.com\/it\/evolocumab-stabilizza-le-placche-nel-90-dei-pazienti-con-sindrome-coronarica-acuta\/"},"pt_PT":{"locale":"pt_PT","id":325869,"slug":"evolocumab-estabiliza-as-placas-em-90-dos-doentes-com-sindrome-coronaria-aguda","post_title":"Evolocumab estabiliza as placas em 90% dos doentes com s\u00edndrome coron\u00e1ria aguda","href":"https:\/\/medizinonline.com\/pt-pt\/evolocumab-estabiliza-as-placas-em-90-dos-doentes-com-sindrome-coronaria-aguda\/"},"es_ES":{"locale":"es_ES","id":325875,"slug":"evolocumab-estabiliza-las-placas-en-el-90-de-los-pacientes-con-sindrome-coronario-agudo","post_title":"Evolocumab estabiliza las placas en el 90% de los pacientes con s\u00edndrome coronario agudo","href":"https:\/\/medizinonline.com\/es\/evolocumab-estabiliza-las-placas-en-el-90-de-los-pacientes-con-sindrome-coronario-agudo\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/325858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=325858"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/325858\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/119678"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=325858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=325858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=325858"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=325858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}